Asian Pacifc Journal of Cancer Prevention, Vol 14, 2013 1677 DOI:http://dx.doi.org/10.7314/APJCP.2013.14.3.1677 Defnitive Chemo-Radiotherapy for Non -Metastatic Esophageal Cancer in North-West Iran Asian Pacifc J Cancer Prev, 14 (3), 1677-1680 Introduction Esophageal cancer is one of the three most common cancers among Iranian people (Sadjadi et al., 2010). The fve-year survival rate in the northern part of Iran is 13% (Ghadimi et al., 2011). DCRT as primary treatment modality is offered to esophageal cancer patients, as an alternative for patients considered medically unft for surgery or having irresectable tumors (Smit et al., 2012). Although DCRT has not been compared directly with surgery in randomized trials, outcomes from published studies are similar to those seen in surgical trials in terms of survival and quality of life (Gwynne et al., 2011). Despite 45 years of the establishment of the regional center of RT, the effect of DCR in survival patients with esophageal cancer has been unknown. The purpose of the current study is to evaluate the effects of DCRT on survival of patients 1 Liver and Gastrointestinal Disease Research Center, 2 Radiation Oncology Therapy of IMAM REZA (AS) Hospital, Tabriz University of Medical Sciences, Tabriz, Iran *For correspondence: mirinezhad@gmail.com Abstract Background: Areas of Iran have among the highest incidences of esophageal cancer in the world. Defnitive chemo-radiotherapy (DCRT) is used for locally advanced esophageal cancer and for inoperable tumors asan alternative to surgical treatment. Materials and Methods: This retrospective study was conducted in North- West Iran 2006-2011, including 267 consecutive patients with non-metastatic esophageal cancer. Eligible inoperable patients were treated with DCRT or defnitive radiotherapy (DRT) alone. Radiotherapy (RT) was delivered at 1.8-2 Gy/day for fve consecutive days in a given week. Chemotherapy (CT) consisted of cisplatin and 5-fuorouracil. Results: The median survival was 12.7 months with 1, 3 and 5 year survival rates of 55%, 18% and 11%, respectively. On univariate analysis, relations with age at diagnosis (p=0.015), N-stage (p=0.04), total dose of RT (p=0.001), fraction (p<0.001), Gap status (p=0.025), chemotherapeutic regimens (P=0.027), and 5-Fu Mg/m 2 (P=0.004) were apparent. Comparing DCRT to DRT, there was a signifcant difference in survival. Multivariate analysis was performed for comparison between DCRT and DRT showed signifcant association with age group ≥65 to <65 (P=0.02; OR: 1.46), the total RT dose (Gy) ≥50 to <50 (P=0.01; OR: 0.65) and the fraction group ≥25 to <25 (P=<0.001; OR: 0.54). Conclusions: The survival rates of esophageal cancer treated with DCRT in North West of Iran is poor; therefore, early detection and improved treatment methods, with clinical trials are a high priority. Keywords: Survival - esophageal cancer - defnitive chemo radiotherapy - North-West Iran RESEARCH ARTICLE Survival in Patients Treated with Definitive Chemo- Radiotherapy for Non-Metastatic Esophageal Cancer in North- West Iran Seyed Kazem Mirinezhad 1 *, Mohammad Hossein Somi 1 , Farshad Seyednezhad 2 , Amir Ghasemi Jangjoo 2 , Morteza Ghojazadeh 1 , Mohammad Mohammadzadeh 2 Ali Reza Naseri 2 , Behnam Nasiri 2 with locally advanced inoperable esophageal cancer and compare two modality treatment. Materials and Methods This retrospective study was conducted in North-West of Iran from March of 2006 to March of 2011, included of 267 consecutive patients with locally advanced inoperable esophageal cancer. Clinical staging consisted of endoscopy, endoscopic ultrasound, barium swallow, computed tomography scan of the abdomen and thorax. Patients with metastatic diseases and those treated with palliative intent (radiation dose <30 Gy) have been excluded. Eligible inoperable patients were treated with DCRT or DRT alone. Clinicopathological variables and survival times were patient’s medical records and collected by telephone contact.